Suggested remit: To appraise the clinical and cost effectiveness of baxdrostat within its marketing authorisation for treating uncontrolled or resistant hypertension.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6623
Provisional Schedule
- Committee meeting:
- 04 November 2026
- Expected publication:
- 14 April 2027
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email TACommD@nice.org.uk
- External Assessment Group:
- Southampton Health Technology Assessment Centre (SHTAC), University of Southampton
Stakeholders
- Companies sponsors
- AstraZeneca (baxdrostat)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Arrhythmia Alliance
- Blood Pressure UK
- British Cardiovascular Society
- Cardiovascular Care Partnership
- Circulation Foundation
- Different Strokes
- Heart UK
- Kidney Care UK
- Kidney Research UK
- National Kidney Federation
- Network of Sikh Organisations
- Pulmonary Hypertension Association UK
- Pumping Marvellous Foundation
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Stroke Association
- Stroke Information
- Sue Ryder
- Professional groups
- Association of Renal Technologists
- British and Irish Association of Stroke Physicians
- British and Irish Hypertension Society
- British Association of Urological Nurses
- British Geriatrics Society
- British Heart Foundation
- British Society for Haematology
- British Society for Haemostasis and Thrombosis
- British Society for Heart Failure
- British Society of Cardiovascular Imaging
- Clinical Leaders of Thrombosis (CLOT)
- National Heart and Lung Institute
- Primary Care Cardiovascular Society
- Royal College of Emergency Medicine
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society for Cardiac Science and Technology
- Society for DGH Nephrologists
- Society for Vascular Technology
- Society of Vascular Nurses
- UK Clinical Pharmacy Association
- UK Kidney Association
- UK Renal Pharmacy Group
- Vascular Society of Great Britain and Ireland
- Assessment group
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- None
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Association of Renal Industries
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- British Society for Cardiovascular Research
- Cochrane Heart, Stroke and Circulation
- Cochrane Hypertension Group
- Cochrane Kidney and Transplant Group
- Cochrane Stroke Group
- European Council for Cardiovascular Research
- Genomics England
- Heart Research UK
- MRC Clinical Trials Unit
- National Centre for Cardiovascular Preventions and Outcomes
- National Institute for Health Research
- The Society for Research in Rehabilitation
- Wellcome Trust
Related links
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 13 April 2026 | Invitation to participate |
| 12 January 2026 - 09 February 2026 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 12 January 2026 | In progress. Scoping commenced. |
| 02 September 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual